- Home
- JPC vs MIRM Comparison
JPC vs MIRM Comparison
Compare JPC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPC
- MIRM
- Stock Information
- Founded
- JPC 2003
- MIRM 2018
- Country
- JPC United States
- MIRM United States
- Employees
- JPC N/A
- MIRM N/A
- Industry
- JPC Investment Managers
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- JPC Finance
- MIRM Health Care
- Exchange
- JPC Nasdaq
- MIRM Nasdaq
- Market Cap
- JPC 2.6B
- MIRM 2.5B
- IPO Year
- JPC N/A
- MIRM 2019
- Fundamental
- Price
- JPC $7.99
- MIRM $52.45
- Analyst Decision
- JPC
- MIRM Strong Buy
- Analyst Count
- JPC 0
- MIRM 11
- Target Price
- JPC N/A
- MIRM $57.00
- AVG Volume (30 Days)
- JPC 998.5K
- MIRM 548.9K
- Earning Date
- JPC 01-01-0001
- MIRM 02-26-2025
- Dividend Yield
- JPC 7.57%
- MIRM N/A
- EPS Growth
- JPC N/A
- MIRM N/A
- EPS
- JPC N/A
- MIRM N/A
- Revenue
- JPC N/A
- MIRM $307,028,000.00
- Revenue This Year
- JPC N/A
- MIRM $83.04
- Revenue Next Year
- JPC N/A
- MIRM $27.22
- P/E Ratio
- JPC N/A
- MIRM N/A
- Revenue Growth
- JPC N/A
- MIRM 112.14
- 52 Week Low
- JPC $5.94
- MIRM $23.14
- 52 Week High
- JPC $7.36
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- JPC 48.71
- MIRM 64.07
- Support Level
- JPC $7.97
- MIRM $51.02
- Resistance Level
- JPC $8.04
- MIRM $53.76
- Average True Range (ATR)
- JPC 0.05
- MIRM 2.04
- MACD
- JPC -0.00
- MIRM 0.03
- Stochastic Oscillator
- JPC 40.00
- MIRM 73.31
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.